Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 4 (April)

1. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer.
   Obstet Gynecol, 105(4): 731-40. [Abstract] [Full-text]
2. Antidepressant medication use [corrected] and risk of ovarian cancer.
   Obstet Gynecol, 105(4): 725-30. [Abstract] [Full-text]
3. Routine appendectomy in epithelial ovarian carcinoma: is it necessary?
   Obstet Gynecol, 105(4): 719-24. [Abstract] [Full-text]
4. Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma.
   Tumour Biol, 26(1): 9-16. [Abstract] [Full-text]
5. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
   Cancer Res, 65(7): 2882-9. [Abstract] [Full-text]
6. Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets.
   Cancer Res, 65(7): 2617-25. [Abstract] [Full-text]
7. Emerging role of RAB GTPases in cancer and human disease.
   Cancer Res, 65(7): 2516-9. [Abstract] [Full-text]
8. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
   Clin Cancer Res, 11(7): 2686-94. [Abstract] [Full-text]
9. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells.
   Clin Cancer Res, 11(7): 2492-501. [Abstract] [Full-text]
10. Ectopic bioactive luteinizing hormone secretion by a pancreatic endocrine tumor, manifested as luteinized granulosa-thecal cell tumor of the ovaries.
    J Clin Endocrinol Metab, 90(4): 2097-103. [Abstract] [Full-text]
11. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice.
    Cancer Chemother Pharmacol, 55(5): 461-5. [Abstract] [Full-text]
12. StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: immunohistochemical and real-time PCR studies.
    Cancer Sci, 96(4): 232-9. [Abstract] [Full-text]
13. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
    Psychooncology, 14(4): 249-61. [Abstract] [Full-text]
14. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
    Cancer Epidemiol Biomarkers Prev, 14(4): 981-7. [Abstract] [Full-text]
15. Immature ovarian teratoma in a young girl: very short course and lethal outcome. A case report.
    Int J Gynecol Cancer, 15(2): 382-4. [Abstract] [Full-text]
16. Umbilical metastasis (Sister Joseph's nodule) as a first sign of a disseminated ovarian carcinoma: comparative immunohistochemical analysis of primary tumor and its metastases.
    Int J Gynecol Cancer, 15(2): 377-81. [Abstract] [Full-text]
17. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization.
    Int J Gynecol Cancer, 15(2): 261-6. [Abstract] [Full-text]
18. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.
    Int J Gynecol Cancer, 15(2): 255-60. [Abstract] [Full-text]
19. A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat.
    Int J Gynecol Cancer, 15(2): 246-54. [Abstract] [Full-text]
20. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens.
    Int J Gynecol Cancer, 15(2): 240-5. [Abstract] [Full-text]
21. Intraperitoneal hyperthermic chemotherapy in ovarian cancer.
    Int J Gynecol Cancer, 15(2): 233-9. [Abstract] [Full-text]
22. A randomized prospective study of comparison of reservoir ports versus conventional vascular access in advanced-stage ovarian carcinoma cases treated with chemotherapy.
    Int J Gynecol Cancer, 15(2): 228-32. [Abstract] [Full-text]
23. Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
    Int J Gynecol Cancer, 15(2): 224-7. [Abstract] [Full-text]
24. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.
    Int J Gynecol Cancer, 15(2): 217-23. [Abstract] [Full-text]
25. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.
    Int J Gynecol Cancer, 15(2): 209-16. [Abstract] [Full-text]
26. Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review.
    Int J Gynecol Cancer, 15(2): 192-202. [Abstract] [Full-text]
27. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer.
    Int J Gynecol Cancer, 15(2): 183-91. [Abstract] [Full-text]
28. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.
    Mol Cancer Ther, 4(4): 603-11. [Abstract] [Full-text]
29. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
    JAMA, 293(14): 1729-36. [Abstract] [Full-text]
30. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Cancer, 103(8): 1631-43. [Abstract] [Full-text]
31. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk.
    Cancer Detect Prev, 29(2): 124-32. [Abstract] [Full-text]
32. A role for Ubc9 in tumorigenesis.
    Oncogene, 24(16): 2677-83. [Abstract] [Full-text]
33. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation.
    Mol Cancer Res, 3(4): 219-26. [Abstract] [Full-text]
34. Allelic loss studies do not provide evidence for the "endometriosis-as-tumor" theory.
    Fertil Steril, 83: 1134-43. [Abstract] [Full-text]
35. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
    Cancer Res, 65(8): 3243-8. [Abstract] [Full-text]
36. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer.
    Cancer Res, 65(8): 3025-9. [Abstract] [Full-text]
37. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
    Cancer Res, 65(8): 3017-24. [Abstract] [Full-text]
38. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors.
    Clin Cancer Res, 11(8): 3117-25. [Abstract] [Full-text]
39. Single nucleotide polymorphism of pi-class glutathione s-transferase and susceptibility to endometrial carcinoma.
    Clin Cancer Res, 11(8): 2981-5. [Abstract] [Full-text]
40. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
    Clin Cancer Res, 11(8): 2875-8. [Abstract] [Full-text]
41. Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature.
    Diagn Cytopathol, 32(5): 307-9. [Abstract] [Full-text]
42. BRCA1 variants in a family study of African-American and Latina women.
    Hum Genet, 116(6): 497-506. [Abstract] [Full-text]
43. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
    J Natl Cancer Inst, 97(8): 560-6. [Abstract] [Full-text]
44. Future options for first-line therapy of advanced ovarian cancer.
    Int J Gynecol Cancer, 15: 42-50. [Abstract] [Full-text]
45. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
    Int J Gynecol Cancer, 15: 36-41. [Abstract] [Full-text]
46. Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.
    Int J Gynecol Cancer, 15: 31-5. [Abstract] [Full-text]
47. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer.
    Int J Gynecol Cancer, 15: 23-30. [Abstract] [Full-text]
48. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
    Int J Gynecol Cancer, 15: 18-22. [Abstract] [Full-text]
49. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
    Int J Gynecol Cancer, 15: 12-7. [Abstract] [Full-text]
50. Treatment goals in ovarian cancer.
    Int J Gynecol Cancer, 15: 3-11. [Abstract] [Full-text]
51. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
    Ann Oncol, 16(5): 749-55. [Abstract] [Full-text]
52. Dyspnea during thalidomide treatment for advanced ovarian cancer.
    Ann Pharmacother, 39(5): 962-5. [Abstract] [Full-text]
53. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
    Am J Obstet Gynecol, 192(4): 1262-71; discussion 1271-3. [Abstract] [Full-text]
54. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
    Am J Obstet Gynecol, 192(4): 1214-21; discussion 1221-2. [Abstract] [Full-text]
55. A long surviving case of Pseudomeigs' syndrome caused by Krukenberg tumor of the stomach.
    Jpn J Clin Oncol, 35(4): 221-3. [Abstract] [Full-text]
56. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).
    Hum Reprod, 20(5): 1379-85. [Abstract] [Full-text]
57. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
    Br J Cancer, 92(8): 1475-85. [Abstract] [Full-text]
58. Artificial neural network computer prediction of ovarian malignancy in women with adnexal masses.
    Int J Gynaecol Obstet, 89(2): 108-13. [Abstract] [Full-text]
59. L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas.
    Int J Cancer, 115(4): 658-65. [Abstract] [Full-text]
60. Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment.
    Int J Cancer, 115(4): 539-44. [Abstract] [Full-text]
61. Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture.
    Carcinogenesis, 26(5): 951-7. [Abstract] [Full-text]
62. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Int J Radiat Oncol Biol Phys, 62(1): 111-7. [Abstract] [Full-text]
63. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
    Int J Radiat Oncol Biol Phys, 62(1): 104-10. [Abstract] [Full-text]
64. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma.
    J Surg Oncol, 90(2): 51-6; discussion 56-8. [Abstract] [Full-text]
65. Hypertriglyceridaemia and malignancy.
    Int J Clin Pract, 59(2): 253-5. [Abstract] [Full-text]
66. Power Doppler vascularity index for predicting malignancy of adnexal masses.
    Ultrasound Obstet Gynecol, 25(5): 508-13. [Abstract] [Full-text]
67. The role of prophylactic oophorectomy in women undergoing surgery for colorectal cancer.
    Colorectal Dis, 7(3): 214-7. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.